InSilicoTrials and AchilleS Vaccines Join Forces to Create Next-Generation Vaccines and Monoclonal Antibodies against Infectious Diseases


InSilicoTrials and AchilleS Vaccines have announced a strategic alliance that aims to unite visions, skills, experiences, the multidisciplinary collaboration network and interested institutions to accelerate the transition towards a complete realization of “biopharma 4.0” concept with a specific focus on vaccines and monoclonal antibodies against infectious diseases.

The collaboration will build on InSilicoTrials’ existing platform and its InSilicoVaccine Suite to create vertical products based on modified Outer Membrane Vesicles (mOMV). mOMV is a technology already used by AchilleS Vaccines with significant advantages for product development, including large-scale and cost-effective production. It has also demonstrated good tolerability and high immunogenicity in humans, making it an attractive candidate for personalized vaccines.

The partnership will allow AchilleS Vaccines to leverage the wide range of in silico tools provided by InSilicoTrials, among which the Immunogenicity Risk Screen tool, a computational solution that predicts the potential risk of immune responses to new protein sequences. It enables the evaluation of potential immunogenicity risks of new protein sequences in silico, without the need for animal testing, which can accelerate vaccine development and create safer and more effective vaccines.

“We are excited to collaborate with AchilleS Vaccines to develop vaccines that can make a real impact on patients’ lives,” said Luca Emili, CEO of InSilicoTrials. “Our in silico platform and tools have the potential to accelerate the development of new vaccines while reducing the need for animal testing.”

“Since the birth of our company we have dreamed of carrying out a preclinical development of a vaccine or a monoclonal antibody while minimizing waste, which is why the LAB 4.0 project was born. We are now excited to partner with InSilico Trials to take this concept further and extend it to the point where we can simulate the entire biopharmaceutical development chain from lab, to animal testing, to clinic, while dramatically reducing related risks,” said Riccardo Baccheschi, President and CEO of AchilleS Vaccines.

The collaboration agreement between InSilicoTrials and AchilleS Vaccines represents a significant step forward in the development of personalized vaccines that could transform the prevention and treatment of infectious diseases.


InSilicoTrials’ research paper published in the Special Issue “Modeling for Advancing Regulatory Science” by Annals of Biomedical Engineering (ABME)


InSilicoTrials, leading player in using artificial intelligence (AI) and Modeling & Simulation (M&S) for drug and medical device development, is proud to announce that its research paper, Accelerating Digitalization in Healthcare with the InSilicoTrials Cloud-Based Platform: Four Use Cases, has been selected to be part of the Special Issue “Modeling for Advancing Regulatory Science“, released by Annals of Biomedical Engineering (ABME) in occasion of the 50th anniversary of the Biomedical Engineering Society.

Computational modeling and simulation can provide unique insights on how human biology and physiology work and why. In November 2022, the FDA published its first report on the Successes and Opportunities in Modeling & Simulation for FDA, highlighting a selection of modeling and simulation case studies from across FDA and illustrating how these technologies have already been embraced and are playing an important role in helping FDA promote public health.

The Special Issue, which was published on December 23rd, 2022, features an editorial by Tina M. MorrisonJoel D. Stitzel & Steve M. Levine – FDA’s office of Regulatory Science and Innovation – entitled Modeling and Simulation in Biomedical Engineering: Regulatory Science and Innovation for Advancing Public HealthThe authors highlight how the potential of CM&S (Computer Modeling and Simulation) to overcome obstacles in enhancing medical treatments has been well-established.

The editorial recalls that in the last few of years, Congress has urged FDA “to engage with device and drug sponsors to explore greater use, where appropriate, of in silico [clinical] trials for advancing new devices and drug therapy applications.” This highlights a “shift toward a greater reliance on digital evidence from in silico methods in healthcare, opening the door to regulatory pathways in which a collection of computer-based models may be used to reduce, refine, and partially replace both in vivo animal and human experimentation for regulatory purposes.”

The editorial concludes that “the practices we establish today will determine the health of all future generations. The time is now to make the necessary changes, not just to advance and translate science, but to create an equitable and foremost healthcare system based upon it.”

InSilicoTrials is proud and honored to be part of this process, together with its strong network of scientific partners, creating the biggest collection of in silico tools, and democratizing access to this technology for the industry.

InSilicoTrials’ paper discusses four use cases of in silico trials performed using the platform for modeling and simulation, providing insights on how the technology can be used to accelerate the development of new treatments and medical devices. The first application illustrates how in silico approaches can improve the early nonclinical assessment of drug-induced cardiotoxicity risks. The second use case is a virtual reproduction of a bench test for the safety assessment of transcatheter heart valve substitutes. The third and fourth use cases are examples of virtual patients’ generation to evaluate treatment effects in multiple sclerosis and prostate cancer patients, respectively.

“We are honored to have our work recognized by the FDA and ABME,” said Luca Emili, CEO of InSilicoTrials. “Modeling and simulation are becoming increasingly important in the drug and medical device development process, and we believe that our cloud-based platform can play a significant role in helping to accelerate the uptake of these technologies.”

An important step in this direction has already been made with the FDA Modernization Act 2.0 (FDAMA 2.0), a bill aiming to modernize and improve the regulatory process for drugs, with the goal of getting safe and effective products to market more quickly. Animal testing on new medications will no longer be required for FDA approval, thanks to legislation signed by US President Joe Biden at the end of last month. 
The bill represents a radical shift in the way drugs and treatments will be developed.

The InSilicoTrials’ platform is designed to make it easy for researchers and companies to access the latest modeling and simulation tools and resources, without the need for expensive hardware or software. The platform is regulatory compliant and has been used by several leading pharmaceutical and medical device companies.